Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis.
Adverse drug event
Clinical pharmacy
Cost analysis
Drug related problem
Economic evaluation
Internal medicine
Medication review
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
05 Feb 2024
05 Feb 2024
Historique:
received:
30
06
2023
accepted:
30
11
2023
medline:
5
2
2024
pubmed:
5
2
2024
entrez:
5
2
2024
Statut:
aheadofprint
Résumé
Adverse drug events contribute to rising health care costs. Clinical pharmacists can reduce their risks by identifying and solving drug-related problems (DRPs) through medication review. To develop an economic model to determine whether medication reviews performed by clinical pharmacists could lead to a reduction in health care costs associated with the prevention of potential adverse drug events. Two pharmacists performed medication reviews during ward rounds in an internal medicine setting over one year. Avoided costs were estimated by monetizing five categories of DRPs (improper drug selection, drug interactions, untreated indications, inadequate dosages, and drug use without an indication). An expert panel assessed potential adverse drug events and their probabilities of occurrence for 20 randomly selected DRPs in each category. The costs of adverse drug events were extracted from internal hospital financial data. A partial economic study from a hospital perspective then estimated the annual costs avoided by resolving DRPs identified by 3 part-time clinical pharmacists (0.9 full-time equivalent) from 2019 to 2020. The return on investment (ROI) of medication review was calculated. The estimated annual avoided costs associated with the potential adverse drug events induced by 676 DRPs detected was € 304,170. The cost of a 0.9 full-time equivalent clinical pharmacist was € 112,408. Extrapolated to 1 full-time equivalent, the annual net savings was € 213,069 or an ROI of 1-1.71. Sensitivity analyses showed that the economic model was robust. This economic model revealed the positive financial impact and favorable return on investment of a medication review intervention performed by clinical pharmacists. These findings should encourage the future deployment of a pharmacist-led adverse drug events prevention program.
Sections du résumé
BACKGROUND
BACKGROUND
Adverse drug events contribute to rising health care costs. Clinical pharmacists can reduce their risks by identifying and solving drug-related problems (DRPs) through medication review.
AIM
OBJECTIVE
To develop an economic model to determine whether medication reviews performed by clinical pharmacists could lead to a reduction in health care costs associated with the prevention of potential adverse drug events.
METHOD
METHODS
Two pharmacists performed medication reviews during ward rounds in an internal medicine setting over one year. Avoided costs were estimated by monetizing five categories of DRPs (improper drug selection, drug interactions, untreated indications, inadequate dosages, and drug use without an indication). An expert panel assessed potential adverse drug events and their probabilities of occurrence for 20 randomly selected DRPs in each category. The costs of adverse drug events were extracted from internal hospital financial data. A partial economic study from a hospital perspective then estimated the annual costs avoided by resolving DRPs identified by 3 part-time clinical pharmacists (0.9 full-time equivalent) from 2019 to 2020. The return on investment (ROI) of medication review was calculated.
RESULTS
RESULTS
The estimated annual avoided costs associated with the potential adverse drug events induced by 676 DRPs detected was € 304,170. The cost of a 0.9 full-time equivalent clinical pharmacist was € 112,408. Extrapolated to 1 full-time equivalent, the annual net savings was € 213,069 or an ROI of 1-1.71. Sensitivity analyses showed that the economic model was robust.
CONCLUSION
CONCLUSIONS
This economic model revealed the positive financial impact and favorable return on investment of a medication review intervention performed by clinical pharmacists. These findings should encourage the future deployment of a pharmacist-led adverse drug events prevention program.
Identifiants
pubmed: 38315303
doi: 10.1007/s11096-023-01683-w
pii: 10.1007/s11096-023-01683-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192–9. https://doi.org/10.1016/s1086-5802(16)31229-3 .
doi: 10.1016/s1086-5802(16)31229-3
Gyllensten H, Rehnberg C, Jönsson AK, et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3:e002574. https://doi.org/10.1136/bmjopen-2013-002574 .
doi: 10.1136/bmjopen-2013-002574
pubmed: 23794552
pmcid: 3686161
Rottenkolber D, Hasford J, Stausberg J. Costs of adverse drug events in German Hospitals—a microcosting study. Value Health. 2012;15:868–75. https://doi.org/10.1016/j.jval.2012.05.007 .
doi: 10.1016/j.jval.2012.05.007
pubmed: 22999137
Shehab N, Lovegrove MC, Geller AI, et al. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316:2115–25. https://doi.org/10.1001/jama.2016.16201 .
doi: 10.1001/jama.2016.16201
pubmed: 27893129
pmcid: 6490178
Hardmeier B, Braunschweig S, Cavallaro M, et al. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly. 2004;134:664–70. https://doi.org/10.4414/smw.2004.10801 .
doi: 10.4414/smw.2004.10801
pubmed: 15611888
Stausberg J. International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA. BMC Health Serv Res. 2014;14:125. https://doi.org/10.1186/1472-6963-14-125 .
doi: 10.1186/1472-6963-14-125
pubmed: 24620750
pmcid: 3984698
Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166:565–71. https://doi.org/10.1001/archinte.166.5.565 .
doi: 10.1001/archinte.166.5.565
pubmed: 16534045
Chen C-C, Hsiao F-Y, Shen L-J, et al. The cost-saving effect and prevention of medication errors by clinical pharmacist intervention in a nephrology unit. Medicine (Baltimore). 2017;96:e7883. https://doi.org/10.1097/MD.0000000000007883 .
doi: 10.1097/MD.0000000000007883
pubmed: 28834903
Chen P-Z, Wu C-C, Huang C-F. Clinical and economic impact of clinical pharmacist intervention in a hematology unit. J Oncol Pharm Pract. 2020;26:866–72. https://doi.org/10.1177/1078155219875806 .
doi: 10.1177/1078155219875806
pubmed: 31566112
Dawoud DM, Smyth M, Ashe J, et al. Effectiveness and cost effectiveness of pharmacist input at the ward level: a systematic review and meta-analysis. Res Soc Adm Pharm. 2019;15:1212–22. https://doi.org/10.1016/j.sapharm.2018.10.006 .
doi: 10.1016/j.sapharm.2018.10.006
English S, Hort A, Sullivan N, et al. Is ward round participation by clinical pharmacists a valuable use of time and money? A time and motion study. Res Soc Adm Pharm. 2020;16:1026–32. https://doi.org/10.1016/j.sapharm.2019.10.014 .
doi: 10.1016/j.sapharm.2019.10.014
Gunterus A, Lopchuk S, Dunn C, et al. Quantitative and economic analysis of clinical pharmacist interventions during rounds in an acute care psychiatric hospital. Ment Health Clin. 2016;6:242–7. https://doi.org/10.9740/mhc.2016.09.242 .
doi: 10.9740/mhc.2016.09.242
pubmed: 29955477
pmcid: 6007593
Rodrigues CR, Harrington AR, Murdock N, et al. Effect of pharmacy-supported transition-of-care interventions on 30-day readmissions: a systematic review and meta-analysis. Ann Pharmacother. 2017;51:866–89. https://doi.org/10.1177/1060028017712725 .
doi: 10.1177/1060028017712725
pubmed: 28599601
Bethishou L, Herzik K, Fang N, et al. The impact of the pharmacist on continuity of care during transitions of care: a systematic review. J Am Pharm Assoc. 2020;60:163-177.e2. https://doi.org/10.1016/j.japh.2019.06.020 .
doi: 10.1016/j.japh.2019.06.020
Schumock GT, Meek PD, Ploetz PA, et al. Economic evaluations of clinical pharmacy services—1988–1995. Pharmacother J Hum Pharmacol Drug Ther. 1996;16:1188–208. https://doi.org/10.1002/j.1875-9114.1996.tb03049.x .
doi: 10.1002/j.1875-9114.1996.tb03049.x
Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996–2000. Pharmacother J Hum Pharmacol Drug Ther. 2003;23:113–32. https://doi.org/10.1592/phco.23.1.113.31910 .
doi: 10.1592/phco.23.1.113.31910
Perez A, Doloresco F, Hoffman JM, et al. Economic evaluations of clinical pharmacy services: 2001–2005. Pharmacother J Hum Pharmacol Drug Ther. 2009;29:128–128. https://doi.org/10.1592/phco.29.1.128 .
doi: 10.1592/phco.29.1.128
Touchette DR, Doloresco F, Suda KJ, et al. Economic evaluations of clinical pharmacy services: 2006–2010. Pharmacother J Hum Pharmacol Drug Ther. 2014;34:771–93. https://doi.org/10.1002/phar.1414 .
doi: 10.1002/phar.1414
Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36:1101–14. https://doi.org/10.1007/s11096-014-0008-9 .
doi: 10.1007/s11096-014-0008-9
pubmed: 25218003
Mutnick AH, Sterba KJ, Peroutka JA, et al. Cost savings and avoidance from clinical interventions. Am J Health Syst Pharm. 1997;54:392–6.
doi: 10.1093/ajhp/54.4.392
pubmed: 9043561
Nesbit TW, Shermock KM, Bobek MB, et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health Syst Pharm. 2001;58:784–90.
doi: 10.1093/ajhp/58.9.784
pubmed: 11351918
Bosma BE. Pharmacist interventions during patient rounds in two intensive care units: clinical and financial impact. Neth J Med. 2018;76:10.
Jacob S, Britt RB, Bryan WE, et al. Economic outcomes associated with safety interventions by a pharmacist-adjudicated prior authorization consult service. J Manag Care Spec Pharm. 2019;25:411–6. https://doi.org/10.18553/jmcp.2019.25.3.411 .
doi: 10.18553/jmcp.2019.25.3.411
pubmed: 30816815
Simoens S, Jacobs I, Popovian R, et al. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics. 2017;35:1047–62. https://doi.org/10.1007/s40273-017-0529-x .
doi: 10.1007/s40273-017-0529-x
pubmed: 28660473
pmcid: 5606961
Bonnabry P, François O. Return on investment: a practical calculation tool to convince your institution. Eur J Hosp Pharm. 2020;27:111–3. https://doi.org/10.1136/ejhpharm-2018-001733 .
doi: 10.1136/ejhpharm-2018-001733
pubmed: 32133138
Berdot S, Blanc C, Chevalier D, et al. Impact of drug storage systems: a quasi-experimental study with and without an automated-drug dispensing cabinet. Int J Qual Health Care. 2019;31:225–30. https://doi.org/10.1093/intqhc/mzy155 .
doi: 10.1093/intqhc/mzy155
pubmed: 30020459
de Carvalho D, Alvim-Borges JL, Toscano CM. Impact assessment of an automated drug-dispensing system in a tertiary hospital. Clinics. 2017;72:629–36. https://doi.org/10.6061/clinics/2017(10)07 .
doi: 10.6061/clinics/2017(10)07
pubmed: 29160426
Risør BW, Lisby M, Sørensen J. Cost-effectiveness analysis of an automated medication system implemented in a Danish Hospital setting. Value Health. 2017;20:886–93. https://doi.org/10.1016/j.jval.2017.03.001 .
doi: 10.1016/j.jval.2017.03.001
pubmed: 28712617
Claus BOM, Robays H, Decruyenaere J, et al. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups. J Eval Clin Pract. 2014;20:1172–9. https://doi.org/10.1111/jep.12289 .
doi: 10.1111/jep.12289
pubmed: 25470782
Kopp BJ, Mrsan M, Erstad BL, et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64:2483–7. https://doi.org/10.2146/ajhp060674 .
doi: 10.2146/ajhp060674
pubmed: 18029956
Lee AJ, Boro MS, Knapp KK, et al. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm. 2002;59:2070–7.
doi: 10.1093/ajhp/59.21.2070
pubmed: 12434719
Benrimoj SI, Langford JH, Berry G, et al. Economic impact of increased clinical intervention rates in community pharmacy. Pharmacoeconomics. 2000;18:459–68. https://doi.org/10.2165/00019053-200018050-00005 .
doi: 10.2165/00019053-200018050-00005
pubmed: 11151399
Truong H-A, Nicole Groves C, Congdon HB, et al. Potential cost savings of medication therapy management in safety-net clinics. J Am Pharm Assoc. 2015;55:269–72. https://doi.org/10.1331/JAPhA.2015.14062 .
doi: 10.1331/JAPhA.2015.14062
Randolph LA, Walker CK, Nguyen AT, et al. Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center. J Oncol Pharm Pract. 2018;24:3–8. https://doi.org/10.1177/1078155216671189 .
doi: 10.1177/1078155216671189
pubmed: 27682600
Chinthammit C, Armstrong EP, Warholak TL. A cost-effectiveness evaluation of hospital discharge counseling by pharmacists. J Pharm Pract. 2012;25:201–8. https://doi.org/10.1177/0897190011418512 .
doi: 10.1177/0897190011418512
pubmed: 21987529
Jourdan J-P, Muzard A, Goyer I, et al. Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital. Int J Clin Pharm. 2018;40:1474–81. https://doi.org/10.1007/s11096-018-0733-6 .
doi: 10.1007/s11096-018-0733-6
pubmed: 30367375
Ahmad A, Weston PJ, Ahmad M, et al. A cost-benefit analysis of twice-daily consultant ward rounds and clinical input on investigation and pharmacy costs in a major teaching hospital in the UK. BMJ Open. 2015;5:e007367. https://doi.org/10.1136/bmjopen-2014-007367 .
doi: 10.1136/bmjopen-2014-007367
pubmed: 25854972
pmcid: 4390722
Yasunaga D, Tasaka Y, Murakami S, et al. Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan. J Pharm Policy Pract. 2016;10:2. https://doi.org/10.1186/s40545-016-0073-7 .
doi: 10.1186/s40545-016-0073-7
pubmed: 27446592
pmcid: 4955163
Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist’s interventions on cost of drug therapy in intensive care unit. Pharm Pract. 2009;7:81–7. https://doi.org/10.4321/s1886-36552009000200003 .
doi: 10.4321/s1886-36552009000200003
Bao Z, Ji C, Hu J, et al. Clinical and economic impact of pharmacist interventions on sampled outpatient prescriptions in a Chinese teaching hospital. BMC Health Serv Res. 2018;18:519. https://doi.org/10.1186/s12913-018-3306-4 .
doi: 10.1186/s12913-018-3306-4
pubmed: 29973200
pmcid: 6031100
Tasaka Y, Tanaka A, Yasunaga D, et al. Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan. J Pharm Health Care Sci. 2018;4:33. https://doi.org/10.1186/s40780-018-0125-z .
doi: 10.1186/s40780-018-0125-z
pubmed: 30564432
pmcid: 6293536
Tasaka Y, Yasunaga D, Tanaka M, et al. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan. Int J Clin Pharm. 2016;38:321–9. https://doi.org/10.1007/s11096-015-0245-6 .
doi: 10.1007/s11096-015-0245-6
pubmed: 26744362
Griese-Mammen N, Hersberger KE, Messerli M, et al. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018;40:1199–208. https://doi.org/10.1007/s11096-018-0696-7 .
doi: 10.1007/s11096-018-0696-7
pubmed: 30073611
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43. https://doi.org/10.1093/ajhp/47.3.533 .
doi: 10.1093/ajhp/47.3.533
pubmed: 2316538
Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274:29–34. https://doi.org/10.1001/jama.1995.03530010043033 .
doi: 10.1001/jama.1995.03530010043033
pubmed: 7791255
Guignard B, Bonnabry P, Perrier A, et al. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26:399–406. https://doi.org/10.1016/j.ejim.2015.05.012 .
doi: 10.1016/j.ejim.2015.05.012
pubmed: 26066400
Procédure de certification REKOLE®. https://www.hplus.ch/fr/comptabilite/proceduredecertificationrekoler/ . Accessed 6 Jan 2019.
World Health Organization International Classification of Diseases (ICD). https://www.who.int/standards/classifications/classification-of-diseases . Accessed 14 Sep 2023.
World Health Organization ICD Update Platform. https://icd.who.int/icd10updateplatform/ . Accessed 14 May 2020.
Neville HL, Chevalier B, Daley C, et al. Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital. Int J Pharm Pract. 2014;22:216–22. https://doi.org/10.1111/ijpp.12058 .
doi: 10.1111/ijpp.12058
pubmed: 23952872
Gallagher J, Byrne S, Woods N, et al. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014;14:177. https://doi.org/10.1186/1472-6963-14-177 .
doi: 10.1186/1472-6963-14-177
pubmed: 24742158
pmcid: 4020601
Gallagher J, O’Sullivan D, McCarthy S, et al. Structured pharmacist review of medication in older hospitalised patients: a cost-effectiveness analysis. Drugs Aging. 2016;33:285–94. https://doi.org/10.1007/s40266-016-0348-3 .
doi: 10.1007/s40266-016-0348-3
pubmed: 26861468
Calloway S, Akilo HA, Bierman K. Impact of a clinical decision support system on pharmacy clinical interventions, documentation efforts, and costs. Hosp Pharm. 2013;48:744–52. https://doi.org/10.1310/hpj4809-744 .
doi: 10.1310/hpj4809-744
pubmed: 24421548
pmcid: 3857121
Lewkowicz D, Wohlbrandt A, Boettinger E. Economic impact of clinical decision support interventions based on electronic health records. BMC Health Serv Res. 2020;20:871. https://doi.org/10.1186/s12913-020-05688-3 .
doi: 10.1186/s12913-020-05688-3
pubmed: 32933513
pmcid: 7491136
Skalafouris C, Samer C, Stirnemann J, et al. Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. Eur J Hosp Pharm. 2021;30:113–6. https://doi.org/10.1136/ejhpharm-2020-002667 .
doi: 10.1136/ejhpharm-2020-002667
pubmed: 33832918
pmcid: 9986913
D’hulster E, Quintens C, Bisschops R, et al. Cost-effectiveness of check of medication appropriateness: methodological approach. Int J Clin Pharm. 2022;44:399–408. https://doi.org/10.1007/s11096-021-01356-6 .
doi: 10.1007/s11096-021-01356-6
pubmed: 35013878
Bosma LBE, Hunfeld NGM, Quax RAM, et al. The effect of a medication reconciliation program in two intensive care units in the Netherlands: a prospective intervention study with a before and after design. Ann Intensive Care. 2018;8:19. https://doi.org/10.1186/s13613-018-0361-2 .
doi: 10.1186/s13613-018-0361-2
pubmed: 29417295
pmcid: 5803169
Sjölander M, Lindholm L, Pfister B, et al. Impact of clinical pharmacist engagement in ward teams on the number of drug-related readmissions among older patients with dementia or cognitive impairment: an economic evaluation. Res Soc Adm Pharm. 2019;15:287–91. https://doi.org/10.1016/j.sapharm.2018.05.006 .
doi: 10.1016/j.sapharm.2018.05.006
Odeh M, Scullin C, Hogg A, et al. A novel approach to medicines optimisation post-discharge from hospital: pharmacist-led medicines optimisation clinic. Int J Clin Pharm. 2020;42:1036–49. https://doi.org/10.1007/s11096-020-01059-4 .
doi: 10.1007/s11096-020-01059-4
pubmed: 32524511
pmcid: 7476989
Al-Qudah RA, Al-Badriyeh D, Al-Ali FM, et al. Cost-benefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients. J Eval Clin Pract. 2020;26:115–24. https://doi.org/10.1111/jep.13209 .
doi: 10.1111/jep.13209
pubmed: 31234234
Wallerstedt SM, Bladh L, Ramsberg J. A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ Open. 2012;2:e000329. https://doi.org/10.1136/bmjopen-2011-000329 .
doi: 10.1136/bmjopen-2011-000329
pubmed: 22223840
pmcid: 3253415
Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. The Lancet. 2012;379:1310–9. https://doi.org/10.1016/S0140-6736(11)61817-5 .
doi: 10.1016/S0140-6736(11)61817-5
Karnon J, Campbell F, Czoski-Murray C. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). J Eval Clin Pract. 2009;15:299–306. https://doi.org/10.1111/j.1365-2753.2008.01000.x .
doi: 10.1111/j.1365-2753.2008.01000.x
pubmed: 19335488
Twigg MJ, Wright D, Barton G, et al. The pharmacy care plan service: evaluation and estimate of cost-effectiveness. Res Soc Adm Pharm. 2019;15:84–92. https://doi.org/10.1016/j.sapharm.2018.03.062 .
doi: 10.1016/j.sapharm.2018.03.062
Jódar-Sánchez F, Malet-Larrea A, Martín JJ, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33:599–610. https://doi.org/10.1007/s40273-015-0270-2 .
doi: 10.1007/s40273-015-0270-2
pubmed: 25774017
Malet-Larrea A, Goyenechea E, Gastelurrutia MA, et al. Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients. Eur J Health Econ. 2017;18:1069–78. https://doi.org/10.1007/s10198-016-0853-7 .
doi: 10.1007/s10198-016-0853-7
pubmed: 27913940
Elliott RA, Lee CY, Beanland C, et al. Development of a clinical pharmacy model within an Australian home nursing service using co-creation and participatory action research: the Visiting Pharmacist (ViP) study. BMJ Open. 2017;7:e018722. https://doi.org/10.1136/bmjopen-2017-018722 .
doi: 10.1136/bmjopen-2017-018722
pubmed: 29102998
pmcid: 5722093
Karapinar-Çarkit F, Borgsteede SD, Zoer J, et al. Effect of medication reconciliation on medication costs after hospital discharge in relation to hospital pharmacy labor costs. Ann Pharmacother. 2012;46:329–38. https://doi.org/10.1345/aph.1Q520 .
doi: 10.1345/aph.1Q520
pubmed: 22395255
Malone DC, Carter BL, Billups SJ, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Pharmacother J Hum Pharmacol Drug Ther. 2012;20:1149–58. https://doi.org/10.1592/phco.20.15.1149.34590 .
doi: 10.1592/phco.20.15.1149.34590
Hung P-L, Chen J-Y, Chen M-T, et al. The impact of a medication reconciliation programme at geriatric hospital admission: a pre-/postintervention study. Br J Clin Pharmacol. 2019;85:2614–22. https://doi.org/10.1111/bcp.14095 .
doi: 10.1111/bcp.14095
pubmed: 31418902
pmcid: 6848902
Weant KA, Armitstead JA, Ladha AM, et al. Cost effectiveness of a clinical pharmacist on a neurosurgical team. Neurosurgery. 2009;65:946–51. https://doi.org/10.1227/01.NEU.0000347090.22818.35 .
doi: 10.1227/01.NEU.0000347090.22818.35
pubmed: 19834408